Roche and Ionis Collaborates to Develop Ionis’s IONIS-FB-LRx to Treat Complement-Mediated Diseases for $760M

 Roche and Ionis Collaborates to Develop Ionis’s IONIS-FB-LRx to Treat Complement-Mediated Diseases for $760M

Roche and Ionis Collaborates to Develop Ionis’s IONIS-FB-LRx to Treat Complement-Mediated Diseases for $760M

Shots:

  • Ionis to get $75M upfront plus $684M as development, regulatory, sales milestones, license fees and to receive tiered royalties up to 20% on sales. Ionis will be responsible for conducting P-II trial for IONIS-FB-LRx in patients with Geographic Atrophy (GA)
  • Under the agreement, Roche has option to license IONIS-FB-LRx post trial completion and will hold global development and commercialization rights
  • IONIS-FB-LRx is an antisense drug used for reduction of Factor B(FB) in patients with GA and is developed by Ionis’ LIgand Conjugated Antisense (LICA) technology

Click here to read full press release/ article | Ref: Ionis Pharma | Image: The Pharma Letter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post